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Abstract 63 
This study investigated the behaviour and characteristics of soluble microbial products (SMP) in 64 
two anoxic-aerobic membrane bioreactors (MBRs): MBRcontrol and MBRpharma, for treating municipal 65 
wastewater. Both protein and polysaccharides measured exhibited higher concentrations in the 66 
MBRpharma than the MBRcontrol. Molecular weight (MW) distribution analysis revealed that the 67 
presence of pharmaceuticals enhanced the accumulation of SMPs with macro- (13,091 kDa and 1,587 68 
kDa) and intermediate-MW (189 kDa) compounds in the anoxic MBRpharma, while a substantial 69 
decrease was observed in both MBR effluents. Excitation emission matrix (EEM) fluorescence 70 
contours indicated that the exposure to pharmaceuticals seemed to stimulate the production of 71 
aromatic proteins containing tyrosine (10.1-32.6%) and tryptophan (14.7-43.1%), compared to 72 
MBRcontrol (9.9-29.1% for tyrosine; 11.8-42.5% for tryptophan). Gas chromatography - mass 73 
spectrometry (GC-MS) analysis revealed aromatics, long-chain alkanes and esters were the 74 
predominant SMPs in the MBRs. More peaks were present in the aerobic MBRpharma (196) than anoxic 75 
MBRpharma (133). The SMPs identified exhibited both biodegradability and recalcitrance in the MBR 76 
treatment processes. Only 8 compounds in the MBRpharma were the same as in the MBRcontrol. Alkanes 77 
were the most dominant SMPs (51%) in the MBRcontrol, while aromatics were dominant (40%) in the 78 
MBRpharma. A significant decrease in aromatics (from 16 to 7) in the MBRpharma permeate was 79 
observed, compared to the aerobic MBRpharma. Approximately 21% of compounds in the aerobic 80 
MBRcontrol were rejected by membrane filtration, while this increased to 28% in the MBRpharma.. 81 
 82 
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1. Introduction 86 
 87 
Pharmaceutical and personal care products (PPCPs) are considered as “emerging contaminants” 88 
and many of them are frequently detected in wastewater treatment plant (WWTP) effluents, and 89 
surface water and drinking water due to their hydrophilic character and persistence in the aquatic 90 
environment (Verlicchi and Zambello, 2015). Although the presence of these compounds in the 91 
environment corresponds to low concentration levels (from parts per trillion to parts per billion), their 92 
continuous release from WWTPs may pose a potential long-term threat to aquatic and terrestrial 93 
ecosystems (Carballa et al., 2004; Kimura et al., 2007).  94 
Soluble microbial products (SMP) are organic compounds biologically derived from wastewater 95 
treatment processes (Rosenberger et al., 2006; Drews et al., 2007; Liang et al., 2007). Previous studies 96 
have reported considerable variability in the production of SMPs in response to environmental 97 
stresses imposed on the microorganisms, such as the presence of toxic compounds (Avella et al., 2010; 98 
Han et al., 2013; Wu et al., 2015). Han (2013) investigated the effects of continuous Zn (II) exposure 99 
on SMP production, and found that the SMP content in the activated sludge increased slightly at 100 
below 400 mg/L of Zn (II), but rose sharply at 600 and 800 mg/L Zn. Wang and Zhang (2010) 101 
characterized SMPs under stressed conditions and revealed that microorganisms exposed to 50 ppm 102 
CrCl3 increased their generation of low MW hydrophilic protein-like materials. In a recent study on 103 
the effect of continuous Ni(II) exposure on the organic degradation and SMP formation in anaerobic 104 
reactors, Wu et al. (2015) indicated that more protein than polysaccharide was produced, suggesting 105 
the prominent function of protein when reacting to the negative effect of toxic metals. Although a 106 
number of studies on the characteristics and fate of SMPs in different bioreactors for the treatment of 107 
municipal and industrial wastewater and landfill leachate have been carried out (Trzcinski and 108 
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Stuckey, 2010; Wu and Zhou, 2010; Juang et al., 2013), little information is available with regards to 109 
the effects of pharmaceuticals on SMP formation and characterization. 110 
To date, research on SMP production and characterisation has been limited to studies focused on 111 
several major components such as proteins, polysaccharides, humic substances, and fulvic acid 112 
(Barker and Stuckey, 1999; Dignac et al., 2000), and their precise composition remains unclear (Liang 113 
et al., 2007). Furthermore, SMPs have a broad spectrum of molecular weights (MW) ranging from 114 
greater than 100 kDa to less than 1 kDa (Shin and Kang, 2003; Jarusutthirak and Amy, 2006), and 115 
low-MW SMPs are commonly predominant in secondary wastewater effluents (Aquino and Stuckey, 116 
2002). In a previous study on the identification of primary compounds using gas chromatography - 117 
mass spectrometry (GC-MS), Aquino and Stuckey (2004) detected long-chain alkenes and alkanes, as 118 
well as some aromatic compounds in significant concentrations (low mg/L). More recently, Trzcinski 119 
and Stuckey (2009) demonstrated that a number of aliphatic molecules were degraded in the 120 
submerged anaerobic MBR, while some aromatic recalcitrants such as Bis (2-ethylhexy) phthalate 121 
were retained in the MBR permeate. Nevertheless, only a few researchers have focused on the 122 
chemical identification of low-MW SMPs using sophisticated instruments, e.g., GC-MS (Kunacheva 123 
and Stuckey, 2014). Therefore, in order to better understand the fundamental mechanisms of secretion, 124 
fate and biodegradability of individual SMPs in biological wastewater treatment processes, as well as 125 
how to reduce the levels of these compounds in the effluent, more work needs to be done to 126 
specifically identify SMP composition and characteristics. 127 
 Many reported studies indicated that membrane bioreactors (MBRs) are more effective than 128 
conventional activated sludge (CAS) for the removal of pharmaceuticals, due to long sludge retention 129 
times (SRTs), high mixed liquor concentrations, minimal sludge production, and high biomass 130 
diversity (Joss et al., 2005; Kümmerer, 2009). SMP/extracellular polymeric substance (EPS) which 131 
accumulate in MBR systems have been shown to be a consequence of high membrane rejection and 132 
low biodegradability. Their formation, composition and behaviour may become even more complex 133 
in MBR systems compared to conventional CAS due to the MBRs retaining biomass at high cell 134 
retention times (Wang and Waite, 2009; Shen et al., 2010). Furthermore, under environmental stress, 135 
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the cells may produce more EPS and SMPs as a result of metabolic changes in order to survive, 136 
possibly even resulting in cell rupture (Aquino and Stuckey, 2004). Therefore, changes in SMP 137 
quantity and composition may reveal the response and resistance of activated sludge in an MBR to the 138 
exposure to pharmaceuticals. However, changes in SMP concentration and composition have rarely 139 
been examined, and a greater understanding of the role SMPs plays in the resistance of CAS to 140 
pharmaceutical exposure is needed.  141 
In this study, the occurrence and characteristics of SMPs in MBRs treating municipal wastewater 142 
containing pharmaceutical compounds was investigated. The main objectives were to i) characterize 143 
the SMP MW distribution using high performance liquid chromatography (HPLC) - size exclusion 144 
chromatography (SEC); ii) investigate the chemical composition of SMPs using three-dimensional 145 
fluorescence excitation emission matrix (EEM); and iii) identify low-MW SMPs in the biological 146 
treatment processes using GC-MS. 147 
 148 
2. Materials and methodologies 149 
 150 
2.1. Pharmaceuticals 151 
 152 
Eight pharmaceuticals (carbamazepine, ibuprofen, naproxen, diclofenac, caffeine, ketoprofen, 153 
salicylic acid, and clofibric acid) were selected because they are frequently detected in the aquatic 154 
environment (Verlicchi and Zambello, 2015). They were purchased from Sigma-Aldrich (Singapore) 155 
with purity > 99%, and their chemical structures and physicochemical properties are given in 156 
Supplementary Table 1.  157 
 158 
2.2. Lab-scale MBR  159 
 160 
Two identical lab-scale MBR systems, i.e., MBRcontrol and MBRpharma, consisting of an anoxic 161 
compartment (3 L) and an aeration compartment (7 L), were operated in parallel (Figure 1). A hollow 162 
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fiber ultrafiltration (UF) membrane (ZeeWeed 500, GE Singapore), made of polyvinylidene fluoride, 163 
was submerged inside the aerobic compartment, and its effective membrane surface area was 565 cm
2
 164 
with a nominal pore size of 0.04 μm. To control the MBR process, 3 min of filtration followed by 1 165 
min of relaxation was achieved using fully automated SCADA software (IFIX).  166 
The MBRs were inoculated with biomass obtained from Ulu Pandan Wastewater Reclamation 167 
Plant (WRP), Singapore. Synthetic wastewater was used in this study to simulate domestic sewage, 168 
and its chemical composition is given in Table 1. The influent for MBRcontrol and MBRpharma was 169 
prepared in two 70-L glass tanks (maintained at 4°C).The selected pharmaceuticals were spiked into 170 
the influent of the MBRpharma resulting in a final concentration of 25 μg/L for each pharmaceutical. 171 
The concentration of mixed liquor suspended solid (MLSS) in the aeration tank was maintained at 172 
around 3-6 g/L with an average sludge retention time (SRT) of 25 d for each MBR. The hydraulic 173 
retention time (HRT) was approximately 10 h, and a permeate flux of 13 - 15 L/m
2
 h (LMH) was 174 
maintained. Level sensors were installed in the two MBRs to control the feeding of influents and 175 
production of membrane permeates. Both MBRs were fitted with a gas diffuser located on the bottom 176 
of the aeration tank to maintain the dissolved oxygen (DO) concentration in the sludge at about 3-4 177 
mg/L for biological oxidation and to achieve membrane scouring. The TMP was monitored 178 
automatically using a digital pressure gauge (Ashcroft). General parameters, such as membrane flux, 179 
pH, DO, and temperature were automatically recorded using a data logger. After 60 days of 180 
acclimatisation, the activated sludge in both MBRs reached a steady state; thereafter, the two MBRs 181 
were operated continuously for a period of 6 months. 182 
. 183 
2.3. Analytical methods  184 
 185 
2.3.1 Detection of water quality parameters and pharmaceutical concentrations 186 
 187 
Influents, anoxic mixed liquors, aerobic mixed liquors, and membrane effluents were collected 188 
twice a week from the two MBRs for measurement of conventional parameters and pharmaceutical 189 
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concentration. The measurement of MLSS, mixed liquor volatile suspended solids (MLVSS), 190 
chemical oxygen demand (COD), and ammonium (NH4
+
-N) was in accordance with Standard 191 
Methods (APHA, 2005). 192 
Prior to the determination of pharmaceutical concentrations, solid phase extraction (SPE) was 193 
conducted using Oasis HLB cartridges (Waters, Milford, MA, USA). The target pharmaceuticals were 194 
analyzed using an ultra performance liquid chromatography - tandem mass spectrometry system 195 
(LCMS - 8030, Shimadzu, Japan) in both negative and positive ion mode.  Chromatographic 196 
separation was achieved with a Gemini-NX  C18 column (110 Ǻ, 75 x 2.0mm; 3 μm particle size) and 197 
a C18 guard column, both supplied by Merck (Singapore). Separation and detection of the analytes 198 
followed a procedure based on a modification of the methods described by Ternes et al. (2005). 199 
 200 
2.3.2 SMP and EPS extraction 201 
 202 
The extraction of SMPs and bound EPS followed the procedure described by Sponza (2002). 203 
Sludge was harvested following centrifugation at 12,000 g for 15 min; the resulting supernatant 204 
represented the SMPs. Next, the dewatered sludge pellet was washed with saline water (0.9% NaCl 205 
solution) twice prior to extraction. The mixed liquor was then subjected to sonication at 20k Hz for 2 206 
min, and centrifuged at 12,000 g for 15 min. The phenol-sulfuric acid method (Dubois et al., 1956) 207 
and the Lowry method (Lowry et al., 1951) were used for determination of the concentrations of 208 
polysaccharides and proteins, respectively.  209 
 210 
2.3.3 SMP molecular weight  (MW) distribution 211 
 212 
A 10 mL sample was first centrifuged at 10,000 rpm for 10 min and then filtered with a 0.22 mm 213 
PTFE syringe filter (SLFG013NK, Millipore, Millex-FG). A high performance size exclusion 214 
chromatograph (HP-SEC) (Agilent Technologies, 1260 LC system) equipped with the PL Aquagel-215 
OH 8 lm MIXED-M column was used for the MW distribution analysis; Milli-Q water was used as 216 
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the mobile phase at a flow rate of 1 mL min
-1
. Polyethylene glycols (PEGs) and polyethylene oxide 217 
standards with molecular weights of 500 kDa, 70 kDa, 4 kDa, 600 Da and 106 Da were used for the 218 
calibration. MW was calculated according to the calibration curve and a linear relationship was 219 
derived between the log of MW (Da) and retention time (Rt: min) as shown in Eq. (1): 220 
Log (MW) = 9.8823 - 0.6748 (Rt)                                                                                                 Eq. (1) 221 
 222 
2.3.4 Three-dimensional fluorescence excitation emission matrix (EEM)   223 
 224 
Three-dimensional EEM fluorescence spectra were measured using a luminescence spectrometry 225 
(Perkin Elmer LS55 Fluorescence Spectrometer). The spectrometer slits were set at 10 nm for both 226 
excitation and emission and excitation wavelengths were increased from 220 nm to 600 nm in 10 nm 227 
steps; for each excitation wavelength the emission was detected from 300 nm to 550 nm in 10 nm 228 
steps. The software FL Winlab Version 4.00.03 (Perkin Elmer) was employed for handling the EEM 229 
data, which were plotted as elliptically shaped contours.  230 
 231 
2.3.5 Gas chromatography - mass spectrometry (GC-MS) 232 
 233 
In the present study, identification of SMPs was carried out using GC-MS, which allows for the 234 
detection of non-polar, volatile and thermo-stable low-MW (< 500 Da) compounds. Prior to the GC-235 
MS analysis, liquid-liquid extraction was performed on a 100 mL filtered supernatant (< 0.45 μm) 236 
using 70 mL dichloromethane (GC-MS grade, Merck) (Wu and Zhou, 2010), this solvent was selected 237 
because it had been used by previous researchers for SMP analysis using GC-MS (Wu and Zhou, 238 
2010). All glassware was washed with acetone prior to the procedure. Mixing was for 3 minutes by 239 
manually inverting the extraction funnel and separation of the 2 phases occurred over 5 minutes. 240 
Traces of water were removed by mixing the solvent phase with 2 spoons (5 mL) of Na2SO4. The 241 
solvent was evaporated was at 50°C under vacuum until 1 mL of solvent remained. 242 
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The samples were then analyzed using a gas chromatograph (5890 Series) equipped with a 243 
QP2010Ultra Mass Spectrometry Detector (Shimadzu, Japan). The analytes were separated using an 244 
Rtx-5MS column (30 m x 0.25 mm with a film thickness of 0.25 µm). The GC_MS oven temperature 245 
program was: 50 °C, hold 7 min, rate 7 ºC min
-1
 and then thereafter increased to 325°C and hold 14 246 
min. Helium was the carrier gas at a flowrate of 1 mL/min. The injector temperature was set at 270°C, 247 
and the MS was operated in the electron impact ionisation mode (70 eV). The transfer line and ion 248 
source temperatures were 290 and 220 °C, respectively. Scan runs were made with a range from m/z 249 
30 to 580. The chromatograms were analysed using the NIST11 library (National Institute of 250 
Standards and Technology, Gaithersburg, MD, USA, http://www.nist.gov/srd/mslist.htm), and a 251 
match percentage was obtained by comparing the mass spectrum of a peak with that of a known 252 
compound from the library. The retention indexes were calculated by the library according to alkanes 253 
standards retention times (Trzcinski and Stuckey, 2010). Quantification was done separately for each 254 
unknown compound using the alkane with the closest retention time. 255 
 256 
3. Results and discussion 257 
 258 
3.1. Treatment performance of MBR systems 259 
 260 
Basic performance parameters including MLVSS, MLSS, DCOD, and NH4
+
-N are summarized in 261 
Table 2. The average MLSS concentrations ranged from 4.1-4.9 g/L, while the values for MLVSS 262 
were 3.8-4.5 g/L. The SCOD concentration in the effluent of the MBRcontrol and MBRpharma was 10.9 263 
and 14.3 mg/L, resulting in high removals of 97.8% and 97.1%, respectively, indicating the efficiency 264 
of MBRs in wastewater treatment. With respect to NH4
+
-N, average removal efficiencies of 95.8% in 265 
MBRpharma and 95.0% in MBRcontrol were observed. The high rate of nitrification achieved may be due 266 
to the effective retention of slow growing nitrifying microorganisms by the membrane, which cannot 267 
be achieved by gravity clarification in CAS systems (Chang et al., 2002).  268 
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Figure 2 shows the removal efficiencies of selected pharmaceuticals in the MBR mixed liquor and 269 
effluent. As expected, no significant removal of recalcitrant carbamazepine was observed (5.4% and 270 
9.6% for the aerobic stage and MBR permeate, respectively), implying its persistence in CAS and 271 
membrane filtration processes. In contrast, all the highly biodegradable compounds such as caffeine, 272 
ibuprofen and salicylic acid, exhibited high removal rates in both the aerobic stage (99%, 91.4% and 273 
92.2%, respectively) and MBR permeate (99.5%, 98.1% and 94.5%, respectively). This finding is 274 
consistent with previous studies (Kim et al., 2007; Miège et al., 2009; Radjenović et al., 2009), 275 
implying that biodegradation was the main removal mechanism for hydrophilic pharmaceuticals. 276 
Although ketoprofen can serve as a sole substrate for microbial growth, and is considered 277 
biodegradable (Quintana et al., 2005), relatively low removal was obtained in the aerobic stage 278 
(55.7%), but this improved significantly after UF membrane filtration (78.4%). In particular, the 279 
removal of clofibric acid and diclofenac was significantly more efficient due to membrane filtration 280 
(61.8% and 75.2%, respectively) than biodegradation in the aerobic stage (33.4% and 43.1%, 281 
respectively).  282 
 283 
3.2. Profiles of proteins and carbohydrates 284 
 285 
Proteins and carbohydrates are usually found to be the primary components of SMPs in activated 286 
sludge (Kunacheva and Stuckey, 2014; Sheng et al., 2010). The variations in protein and carbohydrate 287 
concentrations are shown Figure 3. The average protein and polysaccharide concentrations were 288 
3.95±0.37 mg/L and 11.79 mg/L±2.44 mg/L [n = 24] in the aerobic MBR stage, while in the MBR 289 
effluent were1.13±0.18 mg/L and 4.09±0.38 mg/L, respectively. This finding agrees with Juang et al. 290 
(2013) who investigated the effects of SMP on MBR fouling potential, and reported that the average 291 
protein and carbohydrate concentrations were 2.32 and 12.07 mg/L in the MBR supernatant, while in 292 
the MBR effluent were 1.14 and 7.39 mg/L, respectively. Moreover, a higher average concentration 293 
(P < 0.05) of protein (1.46 mg/L) and  polysaccharide (4.68 mg/L) was observed in the MBRpharma 294 
effluent compared to that in the MBRcontrol (1.03 mg/L for protein; 4.34 mg/L for polysaccharides), 295 
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implying that the exposure of biomass to pharmaceutical compounds increased the production of 296 
SMPs. Similarly, Aquino and Stuckey (2004) investigated SMP formation in anaerobic chemostats in 297 
the presence of toxic compounds, and reported that with chloroform the normalized accumulation of 298 
SMPs increased from 2% to 8%, whereas with Cr, the normalized  ratio reached as high as 20%.  299 
Production and consumption of soluble organics are dynamic processes, thus the concentrations 300 
measured at any point in time present a momentary equilibrium, which can easily be disturbed and 301 
shifted by changes in the environment (Rosenberger et al., 2006). Substrate utilization, biomass decay, 302 
and EPS hydrolysis are believed to be the major processes contributing to SMP formation (Fenu et al., 303 
2010). It is assumed that the analysed organics analysed were part of the bacterial EPS that was 304 
transferred into the liquid phase of the activated sludge, and thus form the soluble EPS or SMP by a 305 
variety of different mechanisms. Considering the fact that proteins and carbohydrates are the 306 
dominant constituents of cell walls (Pérez Silva et al., 2009),  introduction of pharmaceuticals may 307 
disturb cellular function and damage cell membranes, and inevitably lead to cell lysis and an increase 308 
in SMP concentration. In addition, EPS/SMPs play a key role in protecting the inner microorganisms 309 
against environmental stress (Sheng et al., 2010). In the presence of toxic substances, microbial cells 310 
in activated sludge and biofilms utilized the substrate to generate more EPS, which act as a diffusional 311 
barrier between the cell wall and extreme environments to protect the cells from the harsh 312 
environment.  313 
 314 
3.3. Molecular weight (MW) distribution of SMPs 315 
 316 
The MW distribution of SMP was identified using LC-SEC. Five peaks representing different MW 317 
fractions were identified (Figure 4) in both the MBRcontrol and MBRpharma. Peak 1 (13,091 kDa), and 318 
Peak 2 (1,587 kDa) demonstrates the presence of high-MW (> 500 kDa) SMPs. Peak 3 (189 kDa) and 319 
Peak 4 (53 kDa) indicate intermediate-MW fractions (500 kDa < MW <1 kDa), while Peak 5 (71 Da) 320 
indicates the low-MW fraction (MW < 1 kDa).  321 
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As shown in Figure 4, although the location of the major peaks was similar, the relative intensities 322 
of the major peaks in the two MBRs were different. Compared to MBRcontrol, a significant increase in 323 
the intensities of macro- (13,091 kDa and 1,587 kDa) and intermediate-MW (189 kDa) compounds in 324 
the anoxic MBRpharma was observed, implying that the presence of pharmaceuticals enhanced the 325 
accumulation of high- and intermediate fractions in the MBRpharma during start-up stage. A similar 326 
result was also found by Aquino and Stuckey (2004) who revealed the presence of toxic compounds 327 
(Cr and CHCl3) caused a higher accumulation of SMPs with high-MWs. Likewise, Avella et al. 328 
(2010) indicated that the presence of a cytostatic drug (cyclophosphamide) caused a significant 329 
increase in SMPs in MBR supernatants. The presence of toxic compounds (e.g., pharmaceuticals) 330 
tends to cause cell lysis and release intracellular high MW SMPs in response to environmental stress 331 
(Aquino and Stuckey, 2004). Hence, EPS in a non-hydrolysed form may also constitute part of the 332 
high MW SMP (Aquino and Stuckey, 2004). In addition, although many SMPs produced during 333 
biological treatment were degraded, high MW compounds exposed to a toxic environment were likely 334 
to be degraded more slowly and result in an increase in SMPs (Chen et al., 2014).  335 
In addition, a substantial decrease in the concentrations of macro- (13,091 kDa and 1,587 kDa) and 336 
intermediate-MW compounds (189 kDa and 53 kDa) was observed in the MBR effluent, regardless of 337 
the presence of pharmaceuticals. This finding clearly shows that membrane filtration rejected an 338 
important high MW fraction of the soluble macromolecules in the reactor’s bulk solution. The 339 
intermediate-MW fraction of 53 kDa only appeared in the anoxic supernatant, and was not found in 340 
MBR aerobic supernatant and effluent, regardless of the presence of pharmaceuticals. This 341 
observation suggests that the high- and intermediate- MW species might break down into simpler 342 
low- MW solutes.  343 
 344 
3.4. Excitation emission matrix (EEM) fluorescence contours   345 
 346 
Measurements of EEM fluorescence spectra were carried out to help analyse SMP composition, 347 
and the results are shown in Figure 5. In this present study, five peaks were readily identified in 348 
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different treatment units of both MBRs. The first dominant peak was at the excitation/emission 349 
wavelengths (Ex/Em) of 220/320 nm (Peak A), and is related to aromatic proteins (tyrosine). The 350 
second main peak was at the Ex/Em of 225/362 nm (Peak B), and is associated with aromatic proteins 351 
(tryptophan). The other two peaks were located at Ex/Em of 230/426 nm (Peak C) and 285/394 (Peak 352 
D), are associated with fulvic acid-like and humic acid-like solutes. The last peak (Peak E) at the 353 
Ex/Em of 270/360 nm (Peak E) was described as a tryptophan protein-like solute.  354 
In addition, the location of Peak A was red-shifted (15 nm) along the emission axis in the effluent, 355 
while Peak B demonstrated a blue-shift (5 nm) in the effluent, compared to those in the anoxic mixed 356 
liquor. A red shift is related to the presence of carbonyl containing substituents, hydroxyl, alkoxyl, 357 
amino groups and carboxyl constituents (Wang et al., 2009), while a blue shift is associated with the 358 
decomposition of condensed aromatic moieties, and the breakup of large molecules into smaller 359 
fragments, such as a decrease in the number of aromatic rings, a reduction of conjugated bonds in a 360 
chain structure, a conversion of a linear ring to a non-linear system, or an elimination of particular 361 
functional groups including carbonyl, hydroxyl and amine (Coble, 1996). As mentioned above, the 362 
shift in wavelength indicated that the oxidation stage and properties of organic matter were different 363 
during the biological treatment processes.  364 
In order to further examine the compositional changes of SMPs with the exposure to 365 
pharmaceuticals, a fluorescence regional integration (FRI) analysis (Chen et al., 2003; Wang and 366 
Zhang, 2010; Chen et al., 2014) was also conducted and is shown in Figure 6. Regions I, II, III and IV 367 
represent the tyrosine, tyrosine-like protein, tryptophan and tryptophan-like proteins, respectively. 368 
Regions V and VI represent fulvic acid-like and humic acid-like substances. It can be seen that the 369 
SMPs were dominated by fluorescence in Regions I, III, V and VI. Regions I and III accounted for 370 
more than 45.1% , whereas Regions II and IV accounted for less than 15.5%, implying that the 371 
majority of proteins in the SMPs were both tyrosine and tryptophan over other types of proteins 372 
containing amino acids such as leucine, alanine, glycine, lysine, proline, serine, and threonine etc. 373 
Amino acid composition of proteins is often used to describe protein sequences and to design 374 
predictive algorithms (e.g., the tendency of proteins to crystallize), and the percentage of occurrence 375 
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of specific amino acids in proteins depends on the protein dimensions (Carugo, 2008). It is also worth 376 
noting that down the treatment process from influent to effluent, a significant increase in Regions I 377 
and III was observed, implying that these aromatic amino acids were the most difficult to break down. 378 
Furthermore, each region exhibited different trends to the exposure of pharmaceuticals,  and seemed 379 
to stimulate the production of SMPs in Regions I and III, resulting in an increase in amino acids such 380 
as tyrosine (10.1-32.6%) and tryptophan (14.7-43.1%), compared to MBRcontrol (9.9-29.1% for 381 
tyrosine; 11.8-42.5% for tryptophan). It has been well documented that protein plays a significant role 382 
in microorganisms’ adaptation to the presence of toxic compounds, the mechanisms of which include 383 
sequestrating the metal through binding and mitigating the toxicity by enzymatic detoxification 384 
(Bruins et al., 2000). The protein production in the activated sludge was probably enhanced under 385 
pharmaceutical exposure, implying the important role proteins play in cell adaption to pharmaceutical 386 
toxicity. In contrast, Regions V and VI decreased under the exposure to pharmaceuticals, and the 387 
fulvic acid-like substances reduced from 19.7-35.0% to 17.8-29.5% , while the humic acid-like 388 
substances reduced from 11.7-12.9% to 9.9-11.0%. 389 
 390 
3.5. Identification and characterization of SMPs using GC-MS 391 
 392 
3.5.1 SMPs in the aerobic stage  393 
 394 
Compared to SMPs generated in the anoxic MBRpharma (133) (Supplementary Figure 1), the 395 
number of compounds increased to 196 in the aerobic MBRpharma, and 40 compounds (20%) were 396 
identified with a match percentage greater than 80% (Figure 7a). Increasing SMP formation down the 397 
biological treatment processes might be due to the higher biomass concentrations in the aerobic stage 398 
(Table 2) and the greater growth rate of microorganism leading to higher substrate utilization. The 399 
predominant SMPs were aromatics accounting for 39%, followed by esters (17%), alkanes (14%) and 400 
alcohol (14%) (Figure 8a). This result was consistent with Zhou et al. (2009) who investigated SMPs 401 
in the effluent of a sequencing batch reactor treating distillery wastewater, and found that alkanes and 402 
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esters such as heneicosane (19.8%), hexadecanoic acid, butyl ester (18.4%) and tetratetracontane 403 
(10.4%) were a significant percentage of the total compounds present. In particular, these long-chain 404 
carbohydrates (or alkanes) and esters are frequently reported in biological treatment effluent, and are 405 
known to be the main components of low-MW SMPs in aerobic reactors (Janga et al., 2007; Liang et 406 
al., 2007).  407 
During biological treatment, both biodegradable and refractory organic compounds are released 408 
into the system associated with the lysis of cells. In the present study, the majority of compounds, 409 
such as small organic acids (Heptanoic acid, Octanoic acid,), alcohols (n-Pentadecanol, 1-Decanol, 2-410 
methyl-), short-chain alkanes (2-Dodecene, (Z)-), which were present in the anoxic liquor, could not 411 
be detected in the aerobic liquor (Supplementary Table 1 and Table 3). This finding indicated that 412 
these simple compounds might have been easily biodegraded in the aerobic processes. In contrast, 413 
nearly a quarter of SMPs, due to their chemical structure, e.g., substituted ring compounds, cross-414 
linked cell wall fragments, were present in both the anoxic and aerobic liquors, implying that these 415 
refractory compounds were not easily biodegraded under any form of metabolism. Most of these 416 
compounds were aromatics, such as benzoic acid, 3-methyl-, hydrocinnamic acid, N-Methyl-1H-417 
benzimidazol-2-amine, etc.  418 
In the aerobic stage of the MBRcontrol, 41 peaks (18%) were identified with a match percentage 419 
greater than 80%, while 165 peaks (72%) were unidentified (Figure 7b). Among the dominant 420 
compounds identified were alkanes (51%), aromatics (20%) and esters (17%) (Figure 8b). Only 8 421 
compounds in the MBRpharma (e.g., benzoic acid, dodecanoic acid, 2-butenoic acid, 2-propenylidene 422 
ester, etc.,) were the same as in the MBRcontrol, and this implies that the presence of pharmaceutical 423 
compounds resulted in a shift in SMP production and their properties (Table 3 and 4). Moreover, 424 
certain aromatics (e.g., 3(2H)-pyridazinone, 6-chloro-), esters (e.g., tricosyl pentafluoropropionate), 425 
alkanes (e.g., propane, 1,1,2,3-tetrachloro-) and ketones (e.g., 2-propanone, 1,1,3,3-tetrachloro-), 426 
could only be detected in the aerobic MBRpharma and not in the MBRcontrol. This finding indicates that 427 
these compounds may possibly only be generated during the biological treatment of wastewater 428 
containing pharmaceuticals, although no references can be found on the formation and composition of 429 
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SMPs generated in the treatment of pharmaceutical wastewater. In addition, the presence of 430 
pharmaceuticals also influenced the dominant types of compounds present in wastewater. Alkanes 431 
were the most common SMP (51%) in the MBRcontrol, while aromatics were the most dominant SMPs 432 
(40%) in the MBRpharma. This suggests that more refractory SMPs are produced in the presence of 433 
pharmaceuticals, because the aromatic compounds are generally more recalcitrant and therefore 434 
represent a major fraction of residual compounds in the MBRpharma.  435 
 436 
3.5.2 SMPs in the MBR effluent 437 
 438 
Fewer compounds with a match percentage greater than 80% (23) were detected in MBRpharma 439 
effluent than those (40) in the MBRpharma aerobic stage (Figure 7c). The dominant compounds were 440 
aromatics (30%), alkanes (22%) and esters (22%) (Figure 8c). The number of esters decreased (from 9 441 
to 5) in the MBRpharma permeate compared to the MBRpharma aerobic stage, and a similar decreasing 442 
trend could also be found with alkanes (Table 3 and 5). Furthermore, all the compounds detected in 443 
the MBRpharma permeate were smaller than 394 Da, while this value was 578 Da in the aerobic 444 
MBRpharma. The rejection of these higher MW compounds may be due to the formation of a tighter gel 445 
layer on the membrane surface, as well as the interactions between microorganisms and the 446 
compounds (e.g., SMP and organic substances such as colloids) that contributed to the formation of 447 
the gel layer (Jarusutthirak and Amy, 2006; Rosenberger et al., 2006). Moreover, it can be seen that 448 
out of the 23 compounds identified in the MBRpharma permeate, 13 compounds were found in the 449 
aerobic liquor. This finding indicates that the SMPs in the aerobic stage and MBR permeate were 450 
more or less similar.  451 
A significant decrease in aromatics (from 16 to 7) in the MBRpharma permeate was observed, 452 
compared to the MBRpharma aerobic mixed liquor. Aromatic SMPs such as benzoic acid, dl-alanyl-l-453 
leucine, glycyl-L-proline, formamide, (2-acetylphenyl)-, and 1h-1-benzazepine, 2,3,4,5-tetrahydro-, 454 
were only detected in the aerobic stage and disappeared in the permeate. This finding is different from 455 
Liang et al. (2007) who investigated SMPs in an MBR operated at different SRTs, and reported that 456 
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the percentage of aromatic compounds in the total SMPs increased after passing through the 457 
membrane. This discrepancy might be due to the different pore sizes of the membranes used in the 458 
two studies (MF with 0.4 µm versus UF with 0.04 µm in this study), and low pressure microfiltration 459 
(MF) MBRs may have lower SMP rejection rates (Juang et al., 2013). In contrast, other recalcitrant 460 
aromatics such as 3(2h)-pyridazinone, 6-chloro-, phenol, 2-chloro-5-methyl-, benzoic acid, 461 
hydrocinnamic acid, 1h-indol-4-ol, and n-methyl-1h-benzimidazol-2-amine, which were found in the 462 
aerobic stage, were still present in the MBR permeate and clearly difficult to remove through 463 
membrane rejection. Although these recalcitrant aromatic compounds shared the same characteristics 464 
as the selected pharmaceuticals, such as a 6 carbon ring fused to a 5 carbon ring, or rings containing 465 
nitrogen or oxygen with a double bond, there was no strong evidence from the literature to conclude 466 
that these compounds were the degradation by-products of the selected pharmaceuticals.  467 
The total number of peaks found in the MBRcontrol effluent was 181(Figure 7d), and alkane was the 468 
dominant compound in the MBRcontrol effluent (Figure 8d). Table 6 shows the compounds detected in 469 
the MBRcontrol effluent. Approximately 21% of the compounds in the aerobic MBRcontrol were rejected 470 
by the membrane, while this number was lower than the MBRpharma (28%).  Avella et al. (2010) 471 
reported that membranes could reject up to 95% of proteins and up to 68% of polysaccharides in the 472 
MBRpharma, while the values were 98% and 92% in the MBRcontrol , respectively. Previous studies have 473 
identified the EPS/SMP as one of the most significant factors responsible for membrane fouling 474 
(Jarusutthirak and Amy, 2006; Janga et al., 2007), and cake resistance was found to be strongly 475 
related to SMP content in the supernatant (Meng et al., 2009). Indeed, the accumulation of EPS in the 476 
MBR mix liquor would have facilitated the formation of an EPS fouling gel layer on the membrane 477 
surface and eventually lead to pore blocking. Therefore, an increase in the EPS/SMP when cultures 478 
are exposed to pharmaceuticals would inevitably result in increasing membrane fouling. 479 
 480 
4. Conclusions 481 
 482 
18 
   
In the present study, the accumulation, composition, and characteristics of SMPs was examined in 483 
an MBR treating wastewater containing pharmaceutical compounds. The exposure of biomass to 484 
pharmaceutical compounds increased the production of SMPs, and a higher average concentration (P > 485 
0.05) of protein (1.46 mg/L) and  polysaccharides (4.68 mg/L) was observed in the MBRpharma effluent 486 
compared to that in the MBRcontrol (1.03 mg/L for protein; 4.34 mg/L for polysaccharides). HPLC-487 
SEC analysis revealed that the presence of pharmaceuticals enhanced the accumulation of high- and 488 
intermediate MW fractions in the MBRpharma. Measurements of EEM fluorescence spectra indicated 489 
that exposure to pharmaceuticals seemed to stimulate the production of tyrosine and tryptophan 490 
containing solutes. GC-MS analysis revealed that there were clear differences in the SMPs between 491 
the MBRcontrol and MBRpharma in terms of the number of compounds, predominant types of organics, 492 
their concentration and molecular weight, biodegradability and recalcitrance, implying that the 493 
presence of pharmaceutical compounds have caused a radical shift in the SMPs produced. 494 
 495 
 496 
 497 
 498 
 499 
 500 
 501 
 502 
 503 
 504 
 505 
 506 
 507 
 508 
 509 
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